http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Clinical Significance of Bronchodilator Response (BD) in COPD
( Yejin Lee ),( Youlim Kim ),( Hyun Lee ),( Soojie Chung ),( Hayoung Choi ),( Chang Youl Lee ),( Yong Il Hwang ),( Seung Hun Jang ),( Yong Bum Park ) 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.-
Background Clinical significance and characteristics of COPD patients with bronchodilator response (BD) has not been characterized rigorously in previous researches. We aim to investigate whether there is difference with characteristics and exacerbation rate in patients with BD among COPD patients. Methods We performed retrospective comparative analysis of clinical characteristics, moderate and severe exacerbation rate in COPD patients who completed the lung function at least three times with either BD positive or negative. In total, 319 patients (33.5% with BD positive and 66.5% with BD negative) were included in the analysis. Results Compared with BD negative patients, there was no significant difference with age, sex, smoking status, and comorbidity in those with BD positive. Mean FEV1(L) (1.5 ± 0.5) were significantly lower in patients with BD positive than those (1.7 ± 0.7) of BD negative patients. There was no difference with eosinophil count, medication possesion ratio, and inhaler choice except long acting beta agonist. Both moderate and severe exacerbation rate ( 0.05 and 0.06, respectively) and of BD (+) was almost 50% lower than those (0.11 and 0.11, respectively) in the BD negative patients. Conclusion We found that both moderate and severe exacerbation rate was significantly lower in patients with BD positive COPD patients compared with those in BD negative COPD patients.
Noma-like necrotizing stomatitis in a child with Crohn`s disease
( Yejin Lee ),( Ik Jun Moon ),( Woo Jin Lee ),( Chong Hyun Won ),( Sung Eun Chang ),( Mi Woo Lee ),( Jee Ho Choi ),( Ki Chan Moon ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.1
Noma is known to be an opportunistic infection characterized by a devastating gangrenous stomatitis leading to severe tissue destruction. It is associated with high mortality and grotesque disfigurement of the affected area, usually the lips. According to the literature, noma predominantly affects malnourished children in sub-Saharan Africa. Only few cases have been reported in immune compromised patients from developed countries. We present an unusual case of noma-like necrotizing stomatitis in a previously healthy child with Crohn’s disease in Korea. A 11 year-old girl with rapidly progressive necrotic stomatitis of the lower lip was first diagnosed as pyoderma gangrenosum accompanying Crohn’s disease. Steroid pulse therapy was administered to control disease activity which unexpectedly resulted in aggravation of the lesion. Eventually the diagnosis of noma-like necrotizing stomatitis was made. After cessation of systemic steroid and administration broad spectrum antibiotics with intravenous immunoglobulin, the disease slowly improved over a month. However, as the fibrous tissue replaced the whole lips, the patient was left with speech impairment due to buccal stricture and disfigurement. We report this case to increase clinicians’ awareness of the disease and to stress the importance of early recognition and management of this rare disease in order to minimize sequelae.
( Yejin Lee ),( Youlim Kim ),( Chin Kook Rhee ),( Yong Il Hwang ),( Kwang Ha Yoo ),( So Eun Lee ),( Doik Lee ),( Yong Bum Park ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Introduction The most important drug in the treatment of COPD is bronchodilator, and the use of ICS is recommended only in specific condition. However, ICS/LABA continues to be widely prescribed in real practice. We aimed to compare the escalation time to open triple combination therapy from initiation of LAMA vs. ICS/LABA in COPD management in a nationwide real-world setting. Methods Patients who received COPD medication, either LAMA or ICS/LABA, with a diagnostic code of COPD, were selected from the National Health Insurance Service (NHIS) from January 2005 to April 2015. The index date was defined as the first prescription date of LAMA or ICS/LABA with COPD diagnosis during the selection period. Triple combination therapy initiation was defined as claims matched with the same prescription issued on the same date. We excluded patients who had been represcribed with triple therapy within 30 days after the index date. We also investigated the risk factors for triple therapy in crude populations and after propensity score (PS) matching of age, sex, income level, history of asthma, history of pneumonia, history of COPD exacerbation and comorbidity. Results After PS-matching, 2,444 patients were allocated in each LAMA and ICS/LABA group. We assessed the incidence rate of triple combination therapy in LAMA vs. ICS/LABA, where the Results were 81.0 and 139.8 respectively (p <0.001). The escalation time to triple therapy was 281 days in the LAMA group and 207 days in the ICS/LABA group (p=0.03). Compared to LAMA, treatment with ICS/LABA showed a higher risk of triple therapy (HR 1.601, 95% CI [1.402-1.829] (p<0.001)). Male sex was also a risk factor associated with triple therapy (HR [95% CI] 1.564 [1.352-1.809]). Conclusions This analysis shows that the initiation of LAMA therapy was related to a reduced rate of escalation to triple therapy compared to the initiation of ICS/LABA.
ANKRD9 is associated with tumor suppression as a substrate receptor subunit of ubiquitin ligase
Lee, Yejin,Lim, Byungho,Lee, Seon Woo,Lee, Woo Rin,Kim, Yong-In,Kim, Minhyeok,Ju, Hyoungseok,Kim, Mi Young,Kang, Suk-Jo,Song, Ji-Joon,Lee, J. Eugene,Kang, Changwon Elsevier 2018 Biochimica et biophysica acta. Molecular basis of Vol.1864 No.10
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Human <I>ANKRD9</I> (ankyrin repeat domain 9) expression is altered in some cancers.</P> <P><B>Methods</B></P> <P>We tested genetic association of ANKRD9 with gastric cancer susceptibility and examined functional association of ANKRD9 with altered proliferation of MKN45 gastric cancer cells. We then identified ANKRD9-binding partners in HEK 293 embryonic kidney cells using quantitative proteomics, western blotting and complex reconstitution assays. We finally demonstrated ANKRD9's role of recognizing substrates for ubiquitination using in vitro ubiquitylation assay.</P> <P><B>Results</B></P> <P> <I>ANKRD9</I> is associated with cancer susceptibility in a comparison of single-nucleotide polymorphisms between 1092 gastric cancer patients and 1206 healthy controls. ANKRD9 depletion accelerates tumor progression by increasing cellular proliferation, piling up, and anchorage-independent growth of MKN45 cells. We discovered that ANKRD9 is a ubiquitin ligase substrate receptor subunit and has an anti-proliferative activity. ANKRD9 associates with CUL5 (not CUL2), ELOB, ELOC, and presumably RNF7 subunits, which together assemble into a cullin-RING superfamily E3 ligase complex. ANKRD9 belongs to the ASB family of proteins, which are characterized by the presence of ankyrin repeats and a SOCS box. In addition to its interactions with the other E3 ligase subunits, ANKRD9 interacts with two isoforms of inosine monophosphate dehydrogenase (IMPDH). These IMPDH isoforms are cognate substrates of the ANKRD9-containing E3 enzyme, which ubiquitinates them for proteasomal degradation. Their ubiquitination and turnover require the presence of ANKRD9.</P> <P><B>Conclusion</B></P> <P>ANKRD9, a previously unidentified E3 substrate receptor subunit, functions in tumor suppression by recognizing the oncoprotein IMPDH isoforms for E3 ubiquitination and proteasomal degradation.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Human <I>ANKRD9</I> is genetically associated with gastric cancer susceptibility. </LI> <LI> ANKRD9 protein activity is functionally associated with tumor suppression. </LI> <LI> ANKRD9 is a substrate receptor subunit of CUL5-based ubiquitin ligase E3 complex. </LI> <LI> E3 with ANKRD9 ubiquitinates substrate proteins for proteasomal degradation. </LI> <LI> Two isoforms of oncoprotein IMP dehydrogenase are cognate substrates of ANKRD9. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
차량 측면 좁은 공간에 부착할 수 있는 5G 빔포밍 안테나
이예진(Yejin Lee),이경민(Gyungmin Lee),서예준(Yejune Seo),전문수(Munsu Jeon),조정현(Junghyun Cho),이창형(Changhyeong Lee),장지연(Jiyeon Jang),강승택(Sungtek Kahng) 한국통신학회 2021 한국통신학회 학술대회논문집 Vol.2021 No.2
본 논문은 인공지능 차량 및 커넥티드 카에 대한 관심이 높아지면서 이동통신 대역 안테나 또한 차량에 접목이 되고 있다. 이에 증가하는 데이터에 대해 개선하기 위해 측면 좁은 공간에 부착할 수 있는 안테나를 제안하였다. 안테나는 5G 안테나로, 28 GHz 대역에서 동작하는 안테나를 설계하였으며 지향성을 높이기 위해 1X4 안테나를 설계 및 구현하였다.